UBS Group Cuts Globe Life (NYSE:GL) Price Target to $84.00
Globe Life (NYSE:GL) had its target price cut by investment analysts at UBS Group from $85.00 to $84.00 in a research report issued to clients and investors on Thursday, BenzingaRatingsTable reports. The brokerage currently has a “sell” rating on the stock. UBS Group’s target price suggests a potential downside of 10.32% from the company’s current price.
GL has been the subject of several other research reports. ValuEngine lowered shares of Globe Life from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised shares of Globe Life from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a research report on Tuesday, September 3rd. Finally, Credit Suisse Group started coverage on shares of Globe Life in a research report on Friday, September 20th. They issued an “outperform” rating and a $114.00 price objective for the company.
Shares of Globe Life stock traded up $0.82 during trading hours on Thursday, hitting $93.67. The company’s stock had a trading volume of 2,526 shares, compared to its average volume of 416,778. Globe Life has a 1-year low of $69.68 and a 1-year high of $96.92. The firm has a fifty day moving average price of $92.31. The firm has a market cap of $10.23 billion, a P/E ratio of 15.33, a PEG ratio of 1.83 and a beta of 0.95. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.20.
In other news, EVP Vern D. Herbel sold 50,000 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $92.25, for a total value of $4,612,500.00. Following the completion of the sale, the executive vice president now owns 50,000 shares of the company’s stock, valued at $4,612,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Charles E. Adair sold 3,670 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $91.65, for a total transaction of $336,355.50. Following the completion of the sale, the director now directly owns 7,699 shares of the company’s stock, valued at approximately $705,613.35. The disclosure for this sale can be found here. Insiders sold 100,820 shares of company stock valued at $9,241,936 in the last three months. Company insiders own 3.64% of the company’s stock.
Several hedge funds have recently made changes to their positions in GL. Orrstown Financial Services Inc. purchased a new position in shares of Globe Life in the third quarter valued at $56,000. Contravisory Investment Management Inc. purchased a new position in shares of Globe Life in the third quarter valued at $329,000. Everence Capital Management Inc. purchased a new position in shares of Globe Life in the third quarter valued at $585,000. Denali Advisors LLC purchased a new position in shares of Globe Life in the third quarter valued at $689,000. Finally, Mitchell Mcleod Pugh & Williams Inc. purchased a new position in shares of Globe Life in the third quarter valued at $1,050,000. Institutional investors and hedge funds own 75.43% of the company’s stock.
Globe Life Company Profile
Globe Life Inc, through its subsidiaries, provides various life and supplemental health insurance products, and annuities to lower middle to middle income households in the United States. The company operates through four segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Globe Life Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globe Life and related companies with MarketBeat.com's FREE daily email newsletter.